Dr. Reddy’s Laboratories (RDY) CEO API & Services Deepak Sapra resigns effective November 12, 2026

Q: What leadership change did Dr. Reddy’s Laboratories (RDY) disclose in this 6-K?

Dr. Reddy’s disclosed that Mr. Deepak Sapra has resigned as CEO, API and Services and as Senior Management Personnel. He will remain with the company until November 12, 2026 to support transition and handover.

Q: What reason was given for Deepak Sapra’s resignation from Dr. Reddy’s (RDY)?

The company states that Deepak Sapra resigned from his position as CEO, API and Services and Senior Management Personnel to pursue opportunities outside the company , as disclosed under Regulation 30 of the SEBI Listing Regulations.

Q: How long has Deepak Sapra been associated with Dr. Reddy’s Laboratories (RDY)?

In his resignation letter, Deepak Sapra notes over 23 years with Dr. Reddy’s since 2003 . He highlights contributions across various roles, responsibilities and geographies during this long tenure at the organization.

Q: Under which regulation did Dr. Reddy’s (RDY) report the CEO API and Services resignation?

The company reported the resignation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , as referenced along with a related SEBI circular in the annexed details.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited reports that Mr. Deepak Sapra has resigned from his role as CEO, API and Services, and as a member of the company’s Senior Management Personnel to pursue opportunities outside the company. He will remain in employment and part of senior management until the close of business hours on November 12, 2026, providing transition support and handover of responsibilities.

The company states that the disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Sapra’s resignation letter notes his association with Dr. Reddy’s for more than 23 years since 2003 and expresses gratitude for the learning, guidance and support during his tenure.

Positive

None.

Negative

Key business unit CEO resigns: CEO, API and Services and Senior Management Personnel, Mr. Deepak Sapra, will cease employment effective November 12, 2026, creating a leadership transition in an important segment.

Key Figures

Effective cessation date: November 12, 2026 Resignation date: August 13, 2026 Tenure at company: 23+ years

3 metrics

Effective cessation date November 12, 2026 Date on which Deepak Sapra will cease to be in employment and senior management

Resignation date August 13, 2026 Date on which Deepak Sapra submitted his resignation letter

Tenure at company 23+ years Duration of Deepak Sapra’s association with Dr. Reddy’s since 2003

Key Terms

Regulation 30, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Senior Management Personnel, foreign private issuer

4 terms

Regulation 30 regulatory

"Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015"

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory

"Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015"

Senior Management Personnel financial

"has resigned from the position of CEO, API and Services and Senior Management Personnel of the Company"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

What leadership change did Dr. Reddy’s Laboratories (RDY) disclose in this 6-K?

Dr. Reddy’s disclosed that Mr. Deepak Sapra has resigned as CEO, API and Services and as Senior Management Personnel. He will remain with the company until November 12, 2026 to support transition and handover.

When will Deepak Sapra’s resignation at Dr. Reddy’s (RDY) become effective?

Deepak Sapra’s resignation becomes effective from the close of business hours on November 12, 2026. Until that date, he will continue in employment and assist in ensuring a smooth transition of his responsibilities.

What reason was given for Deepak Sapra’s resignation from Dr. Reddy’s (RDY)?

The company states that Deepak Sapra resigned from his position as CEO, API and Services and Senior Management Personnel to pursue opportunities outside the company, as disclosed under Regulation 30 of the SEBI Listing Regulations.

How long has Deepak Sapra been associated with Dr. Reddy’s Laboratories (RDY)?

In his resignation letter, Deepak Sapra notes over 23 years with Dr. Reddy’s since 2003. He highlights contributions across various roles, responsibilities and geographies during this long tenure at the organization.

Under which regulation did Dr. Reddy’s (RDY) report the CEO API and Services resignation?

The company reported the resignation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as referenced along with a related SEBI circular in the annexed details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/13/2026 - 09:52 AM Accepted by SEC EDGAR 08/13/2026 - 09:52 AM

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

August, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit

Number

Description of Exhibits

99.1

Intimation dated August 13,2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)

Date: August 13, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

Exhibit 99.1

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

Email: mail@drreddys.com

Web: www.drreddys.com

August 13, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub:

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Change in Senior Managerial Personnel

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that Mr. Deepak Sapra, has resigned from the position of CEO, API and Services and Senior Management Personnel of the Company. He will cease to be in employment and as part of the Senior Management Personnel of the Company, effective from the close of business hours on November 12, 2026. The resignation letter as received from Mr. Deepak Sapra is annexed herewith.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in Annexure enclosed herewith.

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer and Head-CSR

Encl: as above

Annexure

Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sl. No.	Particulars	Details
1	Reason for change viz. ~~appointment, re-appointment,~~ resignation, ~~removal, death~~ ~~or otherwise;~~	Mr. Deepak Sapra has resigned from the position of CEO, API and Services and Senior Management Personnel of the Company to pursue opportunities outside the Company.
2	Date of ~~appointment/re-appointment/~~cessation ~~(as applicable) & term of~~ ~~appointment/re-appointment~~	November 12, 2026
3	Brief profile (in case of appointment)	Not applicable
4	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

	Dr. Reddy's Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad-500 034, Telangana, India.
	CIN :L85195TG1984PLC004507

	Tel : +91 40 4900 2900
	Fax : + 91 40 4900 2999
	Email : mail@drreddys.com www.drreddys.com

13-Auqust-2026

Mr. Erez Israeli,

Dr. Reddy's Laboratories limited,

Road No. 3, Banjara Hills,

Hyderabad - 500034

Sub: Resignation from Dr. Reddy's

Dear Erez,

I am writing to formally resign from my position as CEO (API and Services) and as a Key Senior Management Personnel at Dr. Reddy's Laboratories in order to pursue opportunities outside the organization. This resignation is made today, the 13th of August, 2026 and I will be with the organization till the 12th of November, 2026.

I will continue to support the organization during this period and ensure a smooth transition and handover of my responsibilities.

I am very thankful to the organization for the learning, guidance and support extended to me over the 23 + years that I have spent here from 2003. This enabled me to contribute across various roles, responsibilities and geographies across the organization.

I wish Dr. Reddy's the very best for the future

Thank you and with best regards,